NA
CRL icon

Navellier & Associates’s Charles River Laboratories CRL Stock Holding History

Navellier & Associates’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,124
Closed -$3.16M – 286
2022
Q1 		$3.16M Sell
11,124
-1,838
-14% -$567K 0.54% 68
2021
Q4 		$4.88M Sell
12,962
-3
-0% -$1.17K 0.71% 42
2021
Q3 		$5.35M Buy
12,965
+382
+3% +$159K 0.81% 38
2021
Q2 		$4.66M Buy
+12,583
New +$4.2M 0.7% 46

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Navellier & Associates's CRL Position: Q2 2022 in Review

Navellier & Associates sold out of Charles River Laboratories (CRL) in Q2 2022, closing a stake of 11,124 shares — an estimated $3.16M sold.

Navellier & Associates first reported a position in CRL in Q2 2021 and held it in 4 quarters. The position peaked at $5.35M in Q3 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

  • Navellier & Associates reported no remaining Charles River Laboratories position as of Q2 2022 after selling out during the quarter.
  • Navellier & Associates sold 11,124 Charles River Laboratories shares in Q2 2022, an estimated $3.16M.
  • Navellier & Associates first reported a position in Charles River Laboratories in Q2 2021 and held it in 4 quarters.
  • Navellier & Associates's Charles River Laboratories position peaked at $5.35M in Q3 2021.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on Navellier & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.